Key result
Midventricular hypertrophic cardiomyopathy was associated with more severe symptoms, smaller left ventricular volumes, and higher cardiac mortality (40% vs 0%, P=0.03) compared to apical HCM.
Observational (n=22)
Answers are grounded in this paper and cite their sources.
In sub-basal HCM, severe symptoms are associated with midventricular hypertrophy, smaller LV volumes, higher filling pressures, and increased mortality compared to apical HCM.
BACKGROUND: We analyzed the clinical and quantitative echocardiographic characteristics of patients with sub-basal hypertrophic cardiomyopathy (HCM) to define the characteristics of patients (pts) with severe symptoms. METHODS: Of 444 pts in a referral-based HCM program, 22 (5%) had midventricular or apical HCM. Quality of life (QoL) questionnaire was administered as an independent confirmer of symptomatic state. RESULTS: Ten pts were NYHA III and IV, and 12 pts were NYHA I and II; QoL scores (41 +/- 26 vs. 10 +/- 13, P = 0.001) confirmed a priori division of two groups based on NYHA classification. Pts with more severe symptoms were more likely female (70% vs. 25%, P = 0.001) with atrial fibrillation (40% vs. 0%, P = 0.02). They more frequently had midventricular HCM 60% versus 8% (P = 0.01) (mid-LV thickness 17 +/- 6 vs. 12 +/- 2 mm, P = 0.03) and had much smaller LV diastolic volumes 68 +/- 12 versus 102 +/- 22 ml (39 +/- 4 vs. 53 +/- 12 ml/m(2), P = 0.001). Septal E/E' was higher in the severely symptomatic pts (15 +/- 5 vs. 7 +/- 3, P = 0.001) indicating higher estimated LV filling pressure. Midobstruction with apical akinetic chamber was noted in 4/10 pts who developed refractory symptoms. Cardiac mortality was higher in the severely symptomatic patients, 4/10 who had midventricular HCM as compared to 0/12 in the mildly symptomatic apical HCM group (P = 0.03). CONCLUSIONS: In subbasal HCM, pts with severe symptoms have midventricular hypertrophy, with encroachment of the LV cavity and consequent very small LV volumes that may be complicated by mid-LV obstruction. Pts with mid-LV hypertrophy are more symptomatic than those with apical HCM, are often refractory to therapy, and have higher mortality.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2009) conducted an observational in Sub-basal hypertrophic cardiomyopathy (midventricular or apical HCM) (n=22). Midventricular HCM / Severe symptoms vs. Apical HCM / Mild symptoms was evaluated on Cardiac mortality (p=0.03). Midventricular hypertrophic cardiomyopathy was associated with more severe symptoms, smaller left ventricular volumes, and higher cardiac mortality (40% vs 0%, P=0.03) compared to apical HCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: